Skip to main content
Premium Trial:

Request an Annual Quote

DoD Restarts Ebola Program with Tekmira


Tekmira Pharmaceuticals this week announced that the US Department of Defense has decided to continue its contract with the company to develop an RNAi-based treatment for Ebola virus infection.

The news is a major boon to Tekmira as the contract represents one of its biggest funding sources.

The firm and the DoD had been working together on an Ebola drug for years, and in 2010, Tekmira received a $34.7 million, three-year contract through the agency's Transformational Medical Technologies program to advance a therapeutic candidate called TKM-Ebola into phase I testing.

The DoD also has the option to extend the arrangement through US Food and Drug Administration approval, which would result in roughly $140 million in funding for Tekmira.

The fate of the alliance had been in question since early August, when Tekmira announced that the DoD had issued a temporary stop-work order on the Ebola contract, citing budgetary constraints (GSN 8/9/2012).

"We are pleased that our productive collaboration with the US DoD's Transformational Medical Technologies program will continue,” Tekmira President and CEO Mark Murray said in a statement. “As we recommence our work, we expect to build on the progress already made with TKM-Ebola and our [lipid nanoparticle] technology platform.”

The Scan

Gone, But Now Reconstructed SARS-CoV-2 Genomes

In a preprint, a researcher describes his recovery of viral sequences that had been removed from a common database.

Rare Heart Inflammation Warning

The Food and Drug Administration is adding a warning about links between a rare inflammatory heart condition and two SARS-CoV-2 vaccines, Reuters reports.

Sandwich Sampling

The New York Times sent tuna sandwiches for PCR analysis.

Nature Papers Describe Gut Viruses, New Format for Storing Quantitative Genomic Data, More

In Nature this week: catalog of DNA viruses of the human gut microbiome, new dense depth data dump format to store quantitative genomic data, and more.